SG192210A1 - (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases - Google Patents

Info

Publication number

SG192210A1

SG192210A1 SG2013057815A SG2013057815A SG192210A1 SG 192210 A1 SG192210 A1 SG 192210A1 SG 2013057815 A SG2013057815 A SG 2013057815A SG 2013057815 A SG2013057815 A SG 2013057815A SG 192210 A1 SG192210 A1 SG 192210A1

Authority

SG

Singapore

Prior art keywords

methyl

triazolo

phenyl

chloro

disorders

Prior art date

2011-01-31

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003112 inhibitor Substances 0.000 title claims abstract description 22
• QNSRYVDGWDXBHV-UHFFFAOYSA-N [1,2,4]triazolo[4,3-a]quinoxaline Chemical class C1=CC=C2N3C=NN=C3C=NC2=C1 QNSRYVDGWDXBHV-UHFFFAOYSA-N 0.000 title abstract description 8
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title description 19
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title description 19
• 150000001875 compounds Chemical class 0.000 claims description 139
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 67
• 125000000217 alkyl group Chemical group 0.000 claims description 45
• 150000003839 salts Chemical class 0.000 claims description 45
• 208000035475 disorder Diseases 0.000 claims description 44
• -1 pyran-4-yl Chemical group 0.000 claims description 43
• 125000005843 halogen group Chemical group 0.000 claims description 40
• 238000011282 treatment Methods 0.000 claims description 33
• 125000001424 substituent group Chemical group 0.000 claims description 27
• 208000024891 symptom Diseases 0.000 claims description 23
• 239000003814 drug Substances 0.000 claims description 20
• 229910052736 halogen Inorganic materials 0.000 claims description 20
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
• 238000000034 method Methods 0.000 claims description 19
• 125000001153 fluoro group Chemical group F* 0.000 claims description 18
• 101100135859 Dictyostelium discoideum regA gene Proteins 0.000 claims description 17
• 101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 claims description 17
• 101100135860 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDE2 gene Proteins 0.000 claims description 17
• 208000020016 psychiatric disease Diseases 0.000 claims description 16
• 150000002367 halogens Chemical class 0.000 claims description 13
• 208000019901 Anxiety disease Diseases 0.000 claims description 11
• 239000003795 chemical substances by application Substances 0.000 claims description 11
• 125000004122 cyclic group Chemical group 0.000 claims description 11
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
• 206010012289 Dementia Diseases 0.000 claims description 10
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 9
• 206010000117 Abnormal behaviour Diseases 0.000 claims description 9
• 241000282414 Homo sapiens Species 0.000 claims description 9
• 208000013403 hyperactivity Diseases 0.000 claims description 9
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 8
• 208000024827 Alzheimer disease Diseases 0.000 claims description 8
• 206010015037 epilepsy Diseases 0.000 claims description 8
• 229910052739 hydrogen Inorganic materials 0.000 claims description 8
• 239000001257 hydrogen Substances 0.000 claims description 8
• 230000003340 mental effect Effects 0.000 claims description 8
• 208000011580 syndromic disease Diseases 0.000 claims description 8
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 7
• 208000016285 Movement disease Diseases 0.000 claims description 7
• 125000003545 alkoxy group Chemical group 0.000 claims description 7
• 229910052801 chlorine Inorganic materials 0.000 claims description 7
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
• 125000005842 heteroatom Chemical group 0.000 claims description 7
• 208000001145 Metabolic Syndrome Diseases 0.000 claims description 6
• 208000008589 Obesity Diseases 0.000 claims description 6
• 229940121828 Phosphodiesterase 2 inhibitor Drugs 0.000 claims description 6
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 6
• 239000004480 active ingredient Substances 0.000 claims description 6
• 230000003542 behavioural effect Effects 0.000 claims description 6
• 230000001149 cognitive effect Effects 0.000 claims description 6
• 230000007812 deficiency Effects 0.000 claims description 6
• 230000006735 deficit Effects 0.000 claims description 6
• 238000011161 development Methods 0.000 claims description 6
• 239000002858 neurotransmitter agent Substances 0.000 claims description 6
• 235000020824 obesity Nutrition 0.000 claims description 6
• 208000012902 Nervous system disease Diseases 0.000 claims description 5
• 230000036541 health Effects 0.000 claims description 5
• 230000035882 stress Effects 0.000 claims description 5
• 208000002705 Glucose Intolerance Diseases 0.000 claims description 4
• 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 4
• 241000124008 Mammalia Species 0.000 claims description 4
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
• 230000001667 episodic effect Effects 0.000 claims description 4
• 230000036651 mood Effects 0.000 claims description 4
• 208000011117 substance-related disease Diseases 0.000 claims description 4
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
• 208000036626 Mental retardation Diseases 0.000 claims description 3
• 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 claims description 3
• 208000027520 Somatoform disease Diseases 0.000 claims description 3
• 239000013543 active substance Substances 0.000 claims description 3
• 210000003169 central nervous system Anatomy 0.000 claims description 3
• 206010012601 diabetes mellitus Diseases 0.000 claims description 3
• 239000003937 drug carrier Substances 0.000 claims description 3
• 125000002757 morpholinyl group Chemical group 0.000 claims description 3
• 230000001314 paroxysmal effect Effects 0.000 claims description 3
• 125000004193 piperazinyl group Chemical group 0.000 claims description 3
• 125000003386 piperidinyl group Chemical group 0.000 claims description 3
• 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
• 125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 claims description 3
• CTBSIWZADWNGPL-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=CC=C3N2C=1C1=CC=CC=C1Cl CTBSIWZADWNGPL-UHFFFAOYSA-N 0.000 claims description 2
• FDXFIVYCNRJKCU-UHFFFAOYSA-N 2-(4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)phenol Chemical compound N=1N=C2C(C)=NC3=CC=CC=C3N2C=1C1=CC=CC=C1O FDXFIVYCNRJKCU-UHFFFAOYSA-N 0.000 claims description 2
• PDPJEMXSHLGRFT-UHFFFAOYSA-N 4-chloro-3-(4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)aniline Chemical compound N=1N=C2C(C)=NC3=CC=CC=C3N2C=1C1=CC(N)=CC=C1Cl PDPJEMXSHLGRFT-UHFFFAOYSA-N 0.000 claims description 2
• KXSGJAHZGIIUIR-UHFFFAOYSA-N 4-methoxy-3-(4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)aniline Chemical compound COC1=CC=C(N)C=C1C1=NN=C2N1C1=CC=CC=C1N=C2C KXSGJAHZGIIUIR-UHFFFAOYSA-N 0.000 claims description 2
• WULGHPGREVSKPP-UHFFFAOYSA-N 4-methyl-3-(4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)aniline Chemical compound CC1=CC=C(N)C=C1C1=NN=C2N1C1=CC=CC=C1N=C2C WULGHPGREVSKPP-UHFFFAOYSA-N 0.000 claims description 2
• 206010003591 Ataxia Diseases 0.000 claims description 2
• 206010003694 Atrophy Diseases 0.000 claims description 2
• 208000027534 Emotional disease Diseases 0.000 claims description 2
• 208000026097 Factitious disease Diseases 0.000 claims description 2
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical group CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims description 2
• 201000001880 Sexual dysfunction Diseases 0.000 claims description 2
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims description 2
• 229960004373 acetylcholine Drugs 0.000 claims description 2
• 230000037444 atrophy Effects 0.000 claims description 2
• 208000018300 basal ganglia disease Diseases 0.000 claims description 2
• 201000003723 learning disability Diseases 0.000 claims description 2
• 229960004640 memantine Drugs 0.000 claims description 2
• 231100000872 sexual dysfunction Toxicity 0.000 claims description 2
• 230000001568 sexual effect Effects 0.000 claims description 2
• 230000009885 systemic effect Effects 0.000 claims description 2
• DGTJUXLZPAKEDG-UHFFFAOYSA-N 1-(2-methoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound COC1=CC=CC=C1C1=NN=C2N1C1=CC=CC=C1N=C2C DGTJUXLZPAKEDG-UHFFFAOYSA-N 0.000 claims 1
• PKFKCXQPEAGAHL-UHFFFAOYSA-N 2-methoxy-6-(4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)phenol Chemical compound COC1=CC=CC(C=2N3C4=CC=CC=C4N=C(C)C3=NN=2)=C1O PKFKCXQPEAGAHL-UHFFFAOYSA-N 0.000 claims 1
• QKWYLCALFFTEAL-UHFFFAOYSA-N 4-methyl-1-(2-nitrophenyl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=CC=C3N2C=1C1=CC=CC=C1[N+]([O-])=O QKWYLCALFFTEAL-UHFFFAOYSA-N 0.000 claims 1
• 125000001188 haloalkyl group Chemical group 0.000 claims 1
• BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
• 208000015114 central nervous system disease Diseases 0.000 abstract description 8
• 101001098814 Dictyostelium discoideum 3',5'-cyclic-nucleotide phosphodiesterase regA Proteins 0.000 abstract description 4
• 235000002639 sodium chloride Nutrition 0.000 description 44
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 35
• WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 34
• 239000000203 mixture Substances 0.000 description 31
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
• 239000005711 Benzoic acid Substances 0.000 description 23
• 235000010233 benzoic acid Nutrition 0.000 description 23
• 201000010099 disease Diseases 0.000 description 23
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 18
• 125000004432 carbon atom Chemical group C* 0.000 description 16
• 230000000694 effects Effects 0.000 description 14
• 238000002360 preparation method Methods 0.000 description 14
• 239000002904 solvent Substances 0.000 description 14
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 13
• 239000000460 chlorine Substances 0.000 description 13
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 12
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
• 102000004190 Enzymes Human genes 0.000 description 12
• 108090000790 Enzymes Proteins 0.000 description 12
• 239000002253 acid Substances 0.000 description 12
• 230000007278 cognition impairment Effects 0.000 description 12
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
• 241000700159 Rattus Species 0.000 description 11
• 229940079593 drug Drugs 0.000 description 11
• 238000002474 experimental method Methods 0.000 description 11
• 239000000243 solution Substances 0.000 description 11
• ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 10
• 241000699670 Mus sp. Species 0.000 description 10
• 208000028017 Psychotic disease Diseases 0.000 description 10
• 230000002903 catalepsic effect Effects 0.000 description 10
• 210000004027 cell Anatomy 0.000 description 10
• 239000012043 crude product Substances 0.000 description 10
• 238000003818 flash chromatography Methods 0.000 description 10
• 239000000126 substance Substances 0.000 description 10
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 9
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
• 241001465754 Metazoa Species 0.000 description 9
• 150000001805 chlorine compounds Chemical class 0.000 description 9
• 239000000543 intermediate Substances 0.000 description 9
• 210000003141 lower extremity Anatomy 0.000 description 9
• 210000001364 upper extremity Anatomy 0.000 description 9
• 208000020925 Bipolar disease Diseases 0.000 description 8
• 238000010171 animal model Methods 0.000 description 8
• 208000010877 cognitive disease Diseases 0.000 description 8
• 235000014113 dietary fatty acids Nutrition 0.000 description 8
• 239000000194 fatty acid Substances 0.000 description 8
• 229930195729 fatty acid Natural products 0.000 description 8
• 230000013016 learning Effects 0.000 description 8
• 230000015654 memory Effects 0.000 description 8
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
• 238000012360 testing method Methods 0.000 description 8
• 206010010904 Convulsion Diseases 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 229940050176 methyl chloride Drugs 0.000 description 7
• 210000001577 neostriatum Anatomy 0.000 description 7
• 201000000980 schizophrenia Diseases 0.000 description 7
• 239000007787 solid Substances 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• PDOPFYRTIVSUKL-UHFFFAOYSA-N 4-(azepan-1-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C1CCCCCN1C1=NC2=CC=CC=C2N2C1=NN=C2 PDOPFYRTIVSUKL-UHFFFAOYSA-N 0.000 description 6
• BXIXXXYDDJVHDL-UHFFFAOYSA-N 4-Chloro-ortho-phenylenediamine Chemical compound NC1=CC=C(Cl)C=C1N BXIXXXYDDJVHDL-UHFFFAOYSA-N 0.000 description 6
• 208000014094 Dystonic disease Diseases 0.000 description 6
• 208000002877 Epileptic Syndromes Diseases 0.000 description 6
• 101001098858 Homo sapiens cGMP-dependent 3',5'-cyclic phosphodiesterase Proteins 0.000 description 6
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
• 208000027089 Parkinsonian disease Diseases 0.000 description 6
• 206010034010 Parkinsonism Diseases 0.000 description 6
• 239000000935 antidepressant agent Substances 0.000 description 6
• 229940005513 antidepressants Drugs 0.000 description 6
• 230000006399 behavior Effects 0.000 description 6
• 102100038953 cGMP-dependent 3',5'-cyclic phosphodiesterase Human genes 0.000 description 6
• 229910052799 carbon Inorganic materials 0.000 description 6
• 230000006870 function Effects 0.000 description 6
• 125000000623 heterocyclic group Chemical group 0.000 description 6
• 238000001727 in vivo Methods 0.000 description 6
• 230000005764 inhibitory process Effects 0.000 description 6
• XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• 230000001105 regulatory effect Effects 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• 208000009132 Catalepsy Diseases 0.000 description 5
• 208000020401 Depressive disease Diseases 0.000 description 5
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
• 101001072037 Homo sapiens cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Proteins 0.000 description 5
• 206010047853 Waxy flexibility Diseases 0.000 description 5
• 230000001430 anti-depressive effect Effects 0.000 description 5
• 230000036506 anxiety Effects 0.000 description 5
• 239000002585 base Substances 0.000 description 5
• 230000036760 body temperature Effects 0.000 description 5
• 229910052794 bromium Inorganic materials 0.000 description 5
• 239000000872 buffer Substances 0.000 description 5
• 102100036377 cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Human genes 0.000 description 5
• 230000018109 developmental process Effects 0.000 description 5
• 229910052731 fluorine Inorganic materials 0.000 description 5
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 239000003176 neuroleptic agent Substances 0.000 description 5
• 230000000701 neuroleptic effect Effects 0.000 description 5
• 230000007170 pathology Effects 0.000 description 5
• 239000008194 pharmaceutical composition Substances 0.000 description 5
• 239000012453 solvate Substances 0.000 description 5
• 241000701447 unidentified baculovirus Species 0.000 description 5
• DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 4
• 208000028698 Cognitive impairment Diseases 0.000 description 4
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
• 239000001828 Gelatine Substances 0.000 description 4
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
• 206010033307 Overweight Diseases 0.000 description 4
• 208000018737 Parkinson disease Diseases 0.000 description 4
• LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 4
• QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 4
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
• 230000002378 acidificating effect Effects 0.000 description 4
• 210000000577 adipose tissue Anatomy 0.000 description 4
• 238000003556 assay Methods 0.000 description 4
• 210000004227 basal ganglia Anatomy 0.000 description 4
• LYQFWZFBNBDLEO-UHFFFAOYSA-M caesium bromide Chemical compound [Br-].[Cs+] LYQFWZFBNBDLEO-UHFFFAOYSA-M 0.000 description 4
• 238000005119 centrifugation Methods 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 4
• ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
• 230000003291 dopaminomimetic effect Effects 0.000 description 4
• 208000010118 dystonia Diseases 0.000 description 4
• 150000004665 fatty acids Chemical class 0.000 description 4
• 238000001914 filtration Methods 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 229920000159 gelatin Polymers 0.000 description 4
• 235000019322 gelatine Nutrition 0.000 description 4
• 210000001320 hippocampus Anatomy 0.000 description 4
• 230000002401 inhibitory effect Effects 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 230000027928 long-term synaptic potentiation Effects 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 210000001010 olfactory tubercle Anatomy 0.000 description 4
• 230000036961 partial effect Effects 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 230000003414 procognitive effect Effects 0.000 description 4
• XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 4
• BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 4
• 229960003147 reserpine Drugs 0.000 description 4
• MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 4
• 208000016686 tic disease Diseases 0.000 description 4
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
• ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 3
• NNDXOASLJBGNDP-UHFFFAOYSA-N 3,6-dichloro-2-methylquinoxaline Chemical compound C1=C(Cl)C=C2N=C(Cl)C(C)=NC2=C1 NNDXOASLJBGNDP-UHFFFAOYSA-N 0.000 description 3
• 229930008281 A03AD01 - Papaverine Natural products 0.000 description 3
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 3
• 208000020706 Autistic disease Diseases 0.000 description 3
• 208000027691 Conduct disease Diseases 0.000 description 3
• 108020004414 DNA Proteins 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 206010020772 Hypertension Diseases 0.000 description 3
• 206010021750 Infantile Spasms Diseases 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• 206010026749 Mania Diseases 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 208000007101 Muscle Cramp Diseases 0.000 description 3
• 206010028980 Neoplasm Diseases 0.000 description 3
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 229920002472 Starch Polymers 0.000 description 3
• 235000021355 Stearic acid Nutrition 0.000 description 3
• 206010043118 Tardive Dyskinesia Diseases 0.000 description 3
• 206010044565 Tremor Diseases 0.000 description 3
• 208000003554 absence epilepsy Diseases 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 235000010443 alginic acid Nutrition 0.000 description 3
• 229920000615 alginic acid Polymers 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 125000004429 atom Chemical group 0.000 description 3
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• 201000011510 cancer Diseases 0.000 description 3
• 230000019771 cognition Effects 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• 230000007850 degeneration Effects 0.000 description 3
• 230000003001 depressive effect Effects 0.000 description 3
• 201000009028 early myoclonic encephalopathy Diseases 0.000 description 3
• ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 3
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
• 201000002904 focal dystonia Diseases 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• 229920006158 high molecular weight polymer Polymers 0.000 description 3
• 150000004677 hydrates Chemical class 0.000 description 3
• 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 3
• XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 230000007257 malfunction Effects 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 229920000609 methyl cellulose Polymers 0.000 description 3
• 235000010981 methylcellulose Nutrition 0.000 description 3
• 239000001923 methylcellulose Substances 0.000 description 3
• 150000007522 mineralic acids Chemical class 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 210000001009 nucleus accumben Anatomy 0.000 description 3
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
• 229960001789 papaverine Drugs 0.000 description 3
• 230000002085 persistent effect Effects 0.000 description 3
• 239000002244 precipitate Substances 0.000 description 3
• 229940002612 prodrug Drugs 0.000 description 3
• 239000000651 prodrug Substances 0.000 description 3
• 108090000623 proteins and genes Proteins 0.000 description 3
• 239000011541 reaction mixture Substances 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• 125000005624 silicic acid group Chemical class 0.000 description 3
• 235000012239 silicon dioxide Nutrition 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 239000008117 stearic acid Substances 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
• GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical class NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• PGXUJKLREVKVQC-UHFFFAOYSA-N 2,6-dichloro-2-methyl-1h-quinoxaline Chemical compound C1=C(Cl)C=C2N=CC(C)(Cl)NC2=C1 PGXUJKLREVKVQC-UHFFFAOYSA-N 0.000 description 2
• NTBQAAGIVDGLLF-UHFFFAOYSA-N 2-[4-chloro-3-(8-chloro-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)phenoxy]-1-pyridin-2-ylethanol Chemical compound Cc1nc2ccc(Cl)cc2n2c(nnc12)-c1cc(OCC(O)c2ccccn2)ccc1Cl NTBQAAGIVDGLLF-UHFFFAOYSA-N 0.000 description 2
• PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
• LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
• NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
• OKPVFVMARCHULN-UHFFFAOYSA-N 5-chloroquinoxaline Chemical class C1=CN=C2C(Cl)=CC=CC2=N1 OKPVFVMARCHULN-UHFFFAOYSA-N 0.000 description 2
• PKVMFWYKYYDTAU-UHFFFAOYSA-N 6-(trifluoromethyl)quinoxaline Chemical class N1=CC=NC2=CC(C(F)(F)F)=CC=C21 PKVMFWYKYYDTAU-UHFFFAOYSA-N 0.000 description 2
• NOYFLUFQGFNMRB-UHFFFAOYSA-N 6-bromoquinoxaline Chemical class N1=CC=NC2=CC(Br)=CC=C21 NOYFLUFQGFNMRB-UHFFFAOYSA-N 0.000 description 2
• AWJVVPSBHNSAAN-UHFFFAOYSA-N 7-chloro-3-methyl-1h-quinoxalin-2-one Chemical compound C1=C(Cl)C=C2NC(=O)C(C)=NC2=C1 AWJVVPSBHNSAAN-UHFFFAOYSA-N 0.000 description 2
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• 208000007415 Anhedonia Diseases 0.000 description 2
• 208000036640 Asperger disease Diseases 0.000 description 2
• 201000006062 Asperger syndrome Diseases 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
• 101100135858 Caenorhabditis elegans pde-2 gene Proteins 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• 201000001913 Childhood absence epilepsy Diseases 0.000 description 2
• 206010008748 Chorea Diseases 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• 208000024254 Delusional disease Diseases 0.000 description 2
• 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 2
• 108090000511 Dopamine D1 Receptors Proteins 0.000 description 2
• 208000012661 Dyskinesia Diseases 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 206010014486 Elevated triglycerides Diseases 0.000 description 2
• 201000011240 Frontotemporal dementia Diseases 0.000 description 2
• 241000206672 Gelidium Species 0.000 description 2
• 208000034308 Grand mal convulsion Diseases 0.000 description 2
• 229920002907 Guar gum Polymers 0.000 description 2
• 108010023302 HDL Cholesterol Proteins 0.000 description 2
• 241000725303 Human immunodeficiency virus Species 0.000 description 2
• 208000023105 Huntington disease Diseases 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• 208000019022 Mood disease Diseases 0.000 description 2
• 208000036572 Myoclonic epilepsy Diseases 0.000 description 2
• LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
• AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
• 201000005625 Neuroleptic malignant syndrome Diseases 0.000 description 2
• 208000025966 Neurological disease Diseases 0.000 description 2
• 239000005642 Oleic acid Substances 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 201000009916 Postpartum depression Diseases 0.000 description 2
• 208000001647 Renal Insufficiency Diseases 0.000 description 2
• 208000005793 Restless legs syndrome Diseases 0.000 description 2
• 208000024791 Schizotypal Personality disease Diseases 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 206010044074 Torticollis Diseases 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
• 201000004810 Vascular dementia Diseases 0.000 description 2
• ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 108060000200 adenylate cyclase Proteins 0.000 description 2
• 102000030621 adenylate cyclase Human genes 0.000 description 2
• WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
• 235000010419 agar Nutrition 0.000 description 2
• 150000001298 alcohols Chemical class 0.000 description 2
• 150000001447 alkali salts Chemical class 0.000 description 2
• 150000001347 alkyl bromides Chemical class 0.000 description 2
• POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 230000001773 anti-convulsant effect Effects 0.000 description 2
• 230000000845 anti-microbial effect Effects 0.000 description 2
• 239000001961 anticonvulsive agent Substances 0.000 description 2
• 239000002249 anxiolytic agent Substances 0.000 description 2
• 230000000949 anxiolytic effect Effects 0.000 description 2
• 206010003246 arthritis Diseases 0.000 description 2
• 125000003118 aryl group Chemical group 0.000 description 2
• MYTWFJKBZGMYCS-NQIIRXRSSA-N bay 60-7550 Chemical compound C1=C(OC)C(OC)=CC=C1CC(NN12)=NC(=O)C1=C(C)N=C2[C@H]([C@@H](C)O)CCCC1=CC=CC=C1 MYTWFJKBZGMYCS-NQIIRXRSSA-N 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 2
• 150000001649 bromium compounds Chemical class 0.000 description 2
• 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
• AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 208000012601 choreatic disease Diseases 0.000 description 2
• 230000002566 clonic effect Effects 0.000 description 2
• 208000028502 clonic seizure Diseases 0.000 description 2
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
• 238000011461 current therapy Methods 0.000 description 2
• JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
• 208000026725 cyclothymic disease Diseases 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
• UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
• POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
• 229960003530 donepezil Drugs 0.000 description 2
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
• 239000003925 fat Substances 0.000 description 2
• 235000019197 fats Nutrition 0.000 description 2
• 150000002191 fatty alcohols Chemical class 0.000 description 2
• 210000005153 frontal cortex Anatomy 0.000 description 2
• 238000007429 general method Methods 0.000 description 2
• HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 2
• 235000010417 guar gum Nutrition 0.000 description 2
• 239000000665 guar gum Substances 0.000 description 2
• 229960002154 guar gum Drugs 0.000 description 2
• 229960003878 haloperidol Drugs 0.000 description 2
• 210000002216 heart Anatomy 0.000 description 2
• KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 2
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
• IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
• 230000000971 hippocampal effect Effects 0.000 description 2
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
• 230000002631 hypothermal effect Effects 0.000 description 2
• 239000005457 ice water Substances 0.000 description 2
• VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 150000004694 iodide salts Chemical class 0.000 description 2
• 201000006370 kidney failure Diseases 0.000 description 2
• 206010023461 kleptomania Diseases 0.000 description 2
• 229910052744 lithium Inorganic materials 0.000 description 2
• 230000004807 localization Effects 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
• 125000002950 monocyclic group Chemical group 0.000 description 2
• WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 210000000956 olfactory bulb Anatomy 0.000 description 2
• 238000010915 one-step procedure Methods 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• 239000003960 organic solvent Substances 0.000 description 2
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
• LPNBBFKOUUSUDB-UHFFFAOYSA-N p-toluenecarboxylic acid Natural products CC1=CC=C(C(O)=O)C=C1 LPNBBFKOUUSUDB-UHFFFAOYSA-N 0.000 description 2
• 208000002851 paranoid schizophrenia Diseases 0.000 description 2
• 230000003950 pathogenic mechanism Effects 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
• XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
• 230000035790 physiological processes and functions Effects 0.000 description 2
• 229920000136 polysorbate Polymers 0.000 description 2
• 208000028173 post-traumatic stress disease Diseases 0.000 description 2
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 201000004645 pyromania Diseases 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 229920002545 silicone oil Polymers 0.000 description 2
• 208000019116 sleep disease Diseases 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 208000012217 specific developmental disease Diseases 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• 210000001103 thalamus Anatomy 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 210000001519 tissue Anatomy 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• SZHOJFHSIKHZHA-UHFFFAOYSA-N tridecanoic acid Chemical compound CCCCCCCCCCCCC(O)=O SZHOJFHSIKHZHA-UHFFFAOYSA-N 0.000 description 2
• 235000013311 vegetables Nutrition 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 230000001755 vocal effect Effects 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• 230000003936 working memory Effects 0.000 description 2
• LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
• NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
• WAMINXJROBOJCS-UHFFFAOYSA-N (3-methylquinoxalin-2-yl)hydrazine Chemical class C1=CC=C2N=C(NN)C(C)=NC2=C1 WAMINXJROBOJCS-UHFFFAOYSA-N 0.000 description 1
• STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
• CXNFPSFLINNWRT-UHFFFAOYSA-N (7-chloro-3-methylquinoxalin-2-yl)hydrazine Chemical compound C1=C(Cl)C=C2N=C(NN)C(C)=NC2=C1 CXNFPSFLINNWRT-UHFFFAOYSA-N 0.000 description 1
• ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
• OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
• RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
• ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
• WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
• QHAIBIZBWSNNOQ-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-7-ol Chemical compound N=1N=C2C(C)=NC3=CC(O)=CC=C3N2C=1C1=CC=CC=C1Cl QHAIBIZBWSNNOQ-UHFFFAOYSA-N 0.000 description 1
• XRRVDIXCRUNODY-UHFFFAOYSA-N 1-(2-chlorophenyl)-7-methoxy-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C=1C(OC)=CC=C(N23)C=1N=C(C)C3=NN=C2C1=CC=CC=C1Cl XRRVDIXCRUNODY-UHFFFAOYSA-N 0.000 description 1
• LDNBSCAOQOOREI-UHFFFAOYSA-N 1-(5-butoxy-2-fluorophenyl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CC=C(F)C(C=2N3C4=CC=CC=C4N=CC3=NN=2)=C1 LDNBSCAOQOOREI-UHFFFAOYSA-N 0.000 description 1
• RBBMQJZCVDIUMH-UHFFFAOYSA-N 1-[2-chloro-5-(4,4,4-trifluorobutoxy)phenyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-7-carbonitrile Chemical compound N=1N=C2C(C)=NC3=CC(C#N)=CC=C3N2C=1C1=CC(OCCCC(F)(F)F)=CC=C1Cl RBBMQJZCVDIUMH-UHFFFAOYSA-N 0.000 description 1
• DHCZQKVLJXPKFJ-UHFFFAOYSA-N 1-[4-chloro-3-(4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)phenoxy]propan-2-ol Chemical compound CC(O)COC1=CC=C(Cl)C(C=2N3C4=CC=CC=C4N=C(C)C3=NN=2)=C1 DHCZQKVLJXPKFJ-UHFFFAOYSA-N 0.000 description 1
• VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
• VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• IBLKWZIFZMJLFL-UHFFFAOYSA-N 1-phenoxypropan-2-ol Chemical compound CC(O)COC1=CC=CC=C1 IBLKWZIFZMJLFL-UHFFFAOYSA-N 0.000 description 1
• XUJLWPFSUCHPQL-UHFFFAOYSA-N 11-methyldodecan-1-ol Chemical compound CC(C)CCCCCCCCCCO XUJLWPFSUCHPQL-UHFFFAOYSA-N 0.000 description 1
• QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
• RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
• JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
• NUMXHEUHHRTBQT-AATRIKPKSA-N 2,4-dimethoxy-1-[(e)-2-nitroethenyl]benzene Chemical compound COC1=CC=C(\C=C\[N+]([O-])=O)C(OC)=C1 NUMXHEUHHRTBQT-AATRIKPKSA-N 0.000 description 1
• XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
• KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
• LCZVSXRMYJUNFX-UHFFFAOYSA-N 2-[2-(2-hydroxypropoxy)propoxy]propan-1-ol Chemical compound CC(O)COC(C)COC(C)CO LCZVSXRMYJUNFX-UHFFFAOYSA-N 0.000 description 1
• AJCFLJFPXFEKEH-UHFFFAOYSA-N 2-[4-chloro-3-(4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)phenoxy]-1-pyridin-2-ylethanone Chemical compound N=1N=C2C(C)=NC3=CC=CC=C3N2C=1C(C(=CC=1)Cl)=CC=1OCC(=O)C1=CC=CC=N1 AJCFLJFPXFEKEH-UHFFFAOYSA-N 0.000 description 1
• 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
• IOILMRUENSKLCV-UHFFFAOYSA-N 2-chloro-3-methyl-6-(trifluoromethyl)quinoxaline Chemical compound FC(F)(F)C1=CC=C2N=C(Cl)C(C)=NC2=C1 IOILMRUENSKLCV-UHFFFAOYSA-N 0.000 description 1
• PXDLUYLWPJMGJA-UHFFFAOYSA-N 2-chloro-3-methylquinoxaline Chemical class C1=CC=C2N=C(Cl)C(C)=NC2=C1 PXDLUYLWPJMGJA-UHFFFAOYSA-N 0.000 description 1
• YZIZOAPUTFGBAP-UHFFFAOYSA-N 2-chloro-6-methoxy-2-methyl-1h-quinoxaline Chemical compound N1C(C)(Cl)C=NC2=CC(OC)=CC=C21 YZIZOAPUTFGBAP-UHFFFAOYSA-N 0.000 description 1
• PKPKWTVSZJVEAR-UHFFFAOYSA-N 2-chloro-n'-(7-chloro-3-methylquinoxalin-2-yl)benzohydrazide Chemical compound CC1=NC2=CC=C(Cl)C=C2N=C1NNC(=O)C1=CC=CC=C1Cl PKPKWTVSZJVEAR-UHFFFAOYSA-N 0.000 description 1
• BYHVGQHIAFURIL-UHFFFAOYSA-N 2-chloroquinoxaline Chemical class C1=CC=CC2=NC(Cl)=CN=C21 BYHVGQHIAFURIL-UHFFFAOYSA-N 0.000 description 1
• ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
• 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
• 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
• 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
• 125000006087 2-oxopyrrolodinyl group Chemical group 0.000 description 1
• WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
• VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
• 125000004610 3,4-dihydro-4-oxo-quinazolinyl group Chemical group O=C1NC(=NC2=CC=CC=C12)* 0.000 description 1
• WYTGWTBNDXWMMB-UHFFFAOYSA-N 3-(8-methoxy-1-methyl-2-oxo-7-phenyl-3h-1,4-benzodiazepin-5-yl)benzamide Chemical compound C1=2C=C(C=3C=CC=CC=3)C(OC)=CC=2N(C)C(=O)CN=C1C1=CC=CC(C(N)=O)=C1 WYTGWTBNDXWMMB-UHFFFAOYSA-N 0.000 description 1
• PRFPCGUDBQRSIX-UHFFFAOYSA-N 3-chloro-2-methyl-6-(trifluoromethyl)quinoxaline Chemical compound C1=C(C(F)(F)F)C=C2N=C(Cl)C(C)=NC2=C1 PRFPCGUDBQRSIX-UHFFFAOYSA-N 0.000 description 1
• WNPOTOPGXJPVHJ-UHFFFAOYSA-N 3-chloro-6-fluoro-2-methylquinoxaline Chemical compound C1=C(F)C=C2N=C(Cl)C(C)=NC2=C1 WNPOTOPGXJPVHJ-UHFFFAOYSA-N 0.000 description 1
• ZDFPVHYZDIODMF-UHFFFAOYSA-N 3-chloro-6-methoxy-3-methyl-2h-quinoxaline Chemical compound C1C(C)(Cl)N=C2C=C(OC)C=CC2=N1 ZDFPVHYZDIODMF-UHFFFAOYSA-N 0.000 description 1
• ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical class OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
• RQWJHUJJBYMJMN-UHFFFAOYSA-N 4-(trifluoromethyl)benzene-1,2-diamine Chemical compound NC1=CC=C(C(F)(F)F)C=C1N RQWJHUJJBYMJMN-UHFFFAOYSA-N 0.000 description 1
• WIHHVKUARKTSBU-UHFFFAOYSA-N 4-bromobenzene-1,2-diamine Chemical compound NC1=CC=C(Br)C=C1N WIHHVKUARKTSBU-UHFFFAOYSA-N 0.000 description 1
• HXCMWAGIKQHTTN-UHFFFAOYSA-N 4-chloro-3-(8-chloro-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)phenol Chemical compound N=1N=C2C(C)=NC3=CC=C(Cl)C=C3N2C=1C1=CC(O)=CC=C1Cl HXCMWAGIKQHTTN-UHFFFAOYSA-N 0.000 description 1
• HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
• KWEWNOOZQVJONF-UHFFFAOYSA-N 4-fluorobenzene-1,2-diamine Chemical compound NC1=CC=C(F)C=C1N KWEWNOOZQVJONF-UHFFFAOYSA-N 0.000 description 1
• HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
• 150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 1
• AGAHETWGCFCMDK-UHFFFAOYSA-N 4-methoxybenzene-1,2-diamine Chemical compound COC1=CC=C(N)C(N)=C1 AGAHETWGCFCMDK-UHFFFAOYSA-N 0.000 description 1
• CSWBESHLLIBAKY-UHFFFAOYSA-N 4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical class CC1=NC2=CC=CC=C2N2C1=NN=C2 CSWBESHLLIBAKY-UHFFFAOYSA-N 0.000 description 1
• 125000005986 4-piperidonyl group Chemical group 0.000 description 1
• 125000001572 5'-adenylyl group Chemical group C=12N=C([H])N=C(N([H])[H])C=1N=C([H])N2[C@@]1([H])[C@@](O[H])([H])[C@@](O[H])([H])[C@](C(OP(=O)(O[H])[*])([H])[H])([H])O1 0.000 description 1
• WZWVTXWJJYIZEM-UHFFFAOYSA-N 5-(trifluoromethyl)quinoxaline Chemical class C1=CN=C2C(C(F)(F)F)=CC=CC2=N1 WZWVTXWJJYIZEM-UHFFFAOYSA-N 0.000 description 1
• UJEGBESUCWOWNQ-UHFFFAOYSA-N 5-bromoquinoxaline Chemical class C1=CN=C2C(Br)=CC=CC2=N1 UJEGBESUCWOWNQ-UHFFFAOYSA-N 0.000 description 1
• DSCYVCLBSVVQDH-UHFFFAOYSA-N 5-fluoroquinoxaline Chemical class C1=CN=C2C(F)=CC=CC2=N1 DSCYVCLBSVVQDH-UHFFFAOYSA-N 0.000 description 1
• UQHNHWHCASOISS-UHFFFAOYSA-N 6-bromo-2-chloro-3-methylquinoxaline Chemical compound BrC1=CC=C2N=C(Cl)C(C)=NC2=C1 UQHNHWHCASOISS-UHFFFAOYSA-N 0.000 description 1
• GCQVXKHFLSRFSR-UHFFFAOYSA-N 6-bromo-3-chloro-2-methylquinoxaline Chemical compound C1=C(Br)C=C2N=C(Cl)C(C)=NC2=C1 GCQVXKHFLSRFSR-UHFFFAOYSA-N 0.000 description 1
• HOOMNCITVCXDTR-UHFFFAOYSA-N 6-chloroquinoxaline Chemical class N1=CC=NC2=CC(Cl)=CC=C21 HOOMNCITVCXDTR-UHFFFAOYSA-N 0.000 description 1
• BURIFIXTNVTJJN-UHFFFAOYSA-N 6-methoxyquinoxaline Chemical class N1=CC=NC2=CC(OC)=CC=C21 BURIFIXTNVTJJN-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• ZDOSWEGEZXKDLA-UHFFFAOYSA-N 8-chloro-1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=C(Cl)C=C3N2C=1C1=CC=CC=C1Cl ZDOSWEGEZXKDLA-UHFFFAOYSA-N 0.000 description 1
• MXIRJRIBGCCKEU-UHFFFAOYSA-N 8-chloro-1-[2-chloro-5-(2-fluoro-2-pyridin-2-ylethoxy)phenyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound Cc1nc2ccc(Cl)cc2n2c(nnc12)-c1cc(OCC(F)c2ccccn2)ccc1Cl MXIRJRIBGCCKEU-UHFFFAOYSA-N 0.000 description 1
• ZBXZRPSWDYVWGF-UHFFFAOYSA-N 8-chloro-3-methyl-1h-quinoxalin-2-one Chemical compound C1=CC(Cl)=C2NC(=O)C(C)=NC2=C1 ZBXZRPSWDYVWGF-UHFFFAOYSA-N 0.000 description 1
• 208000004611 Abdominal Obesity Diseases 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 206010001497 Agitation Diseases 0.000 description 1
• 208000008811 Agoraphobia Diseases 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
• 235000019489 Almond oil Nutrition 0.000 description 1
• 229920000945 Amylopectin Polymers 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 206010002650 Anorexia nervosa and bulimia Diseases 0.000 description 1
• 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
• 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 206010003628 Atonic seizures Diseases 0.000 description 1
• 206010003805 Autism Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 235000021357 Behenic acid Nutrition 0.000 description 1
• DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
• 206010006362 Brief psychotic disorder, with postpartum onset Diseases 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 206010065941 Central obesity Diseases 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 244000060011 Cocos nucifera Species 0.000 description 1
• 235000013162 Cocos nucifera Nutrition 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 208000033001 Complex partial seizures Diseases 0.000 description 1
• 208000032065 Convulsion neonatal Diseases 0.000 description 1
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
• 101150049660 DRD2 gene Proteins 0.000 description 1
• 206010011953 Decreased activity Diseases 0.000 description 1
• 206010012218 Delirium Diseases 0.000 description 1
• 206010012239 Delusion Diseases 0.000 description 1
• 208000032538 Depersonalisation Diseases 0.000 description 1
• 206010012422 Derealisation Diseases 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
• MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
• 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
• 102000004076 Dopamine D1 Receptors Human genes 0.000 description 1
• 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
• 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
• 206010013654 Drug abuse Diseases 0.000 description 1
• 208000005819 Dystonia Musculorum Deformans Diseases 0.000 description 1
• 208000030814 Eating disease Diseases 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 208000016132 Epilepsy with myoclonic absences Diseases 0.000 description 1
• 208000010228 Erectile Dysfunction Diseases 0.000 description 1
• URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 description 1
• 206010015605 Excessive masturbation Diseases 0.000 description 1
• 229940123511 Excitatory amino acid receptor antagonist Drugs 0.000 description 1
• 208000027776 Extrapyramidal disease Diseases 0.000 description 1
• 208000019454 Feeding and Eating disease Diseases 0.000 description 1
• 208000001836 Firesetting Behavior Diseases 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
• 208000001613 Gambling Diseases 0.000 description 1
• 108091006101 Gi proteins Proteins 0.000 description 1
• 102000034354 Gi proteins Human genes 0.000 description 1
• 108091006065 Gs proteins Proteins 0.000 description 1
• 108010078321 Guanylate Cyclase Proteins 0.000 description 1
• 102000014469 Guanylate cyclase Human genes 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 108010010234 HDL Lipoproteins Proteins 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000004547 Hallucinations Diseases 0.000 description 1
• 206010019663 Hepatic failure Diseases 0.000 description 1
• 102000000543 Histamine Receptors Human genes 0.000 description 1
• 108010002059 Histamine Receptors Proteins 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 206010021118 Hypotonia Diseases 0.000 description 1
• 208000030990 Impulse-control disease Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 206010022489 Insulin Resistance Diseases 0.000 description 1
• 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
• 206010071082 Juvenile myoclonic epilepsy Diseases 0.000 description 1
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
• 239000005639 Lauric acid Substances 0.000 description 1
• 201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 1
• 208000009829 Lewy Body Disease Diseases 0.000 description 1
• 201000002832 Lewy body dementia Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 208000026139 Memory disease Diseases 0.000 description 1
• 206010027525 Microalbuminuria Diseases 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 208000002033 Myoclonus Diseases 0.000 description 1
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-methylmorpholine Substances CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
• 206010029333 Neurosis Diseases 0.000 description 1
• 244000061176 Nicotiana tabacum Species 0.000 description 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
• 208000022873 Ocular disease Diseases 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 206010057342 Onychophagia Diseases 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 229910020667 PBr3 Inorganic materials 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 235000021314 Palmitic acid Nutrition 0.000 description 1
• 208000037158 Partial Epilepsies Diseases 0.000 description 1
• 208000022779 Passive-Aggressive Personality disease Diseases 0.000 description 1
• 206010034158 Pathological gambling Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 208000012202 Pervasive developmental disease Diseases 0.000 description 1
• 206010034759 Petit mal epilepsy Diseases 0.000 description 1
• 206010034912 Phobia Diseases 0.000 description 1
• 229940123773 Phosphodiesterase 10A inhibitor Drugs 0.000 description 1
• 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
• 208000027030 Premenstrual dysphoric disease Diseases 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
• HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
• 208000037012 Psychomotor seizures Diseases 0.000 description 1
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
• 241000700157 Rattus norvegicus Species 0.000 description 1
• 208000006289 Rett Syndrome Diseases 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• 229940124639 Selective inhibitor Drugs 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• 206010040703 Simple partial seizures Diseases 0.000 description 1
• 206010041243 Social avoidant behaviour Diseases 0.000 description 1
• 206010041250 Social phobia Diseases 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
• 206010067672 Spasmodic dysphonia Diseases 0.000 description 1
• 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
• 208000013200 Stress disease Diseases 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• 206010073746 Thumb sucking Diseases 0.000 description 1
• 208000023655 Tic Diseases 0.000 description 1
• 208000000323 Tourette Syndrome Diseases 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 201000006791 West syndrome Diseases 0.000 description 1
• 208000013142 Writer cramp Diseases 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 150000008043 acidic salts Chemical class 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 208000012826 adjustment disease Diseases 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001336 alkenes Chemical class 0.000 description 1
• 125000005210 alkyl ammonium group Chemical group 0.000 description 1
• 150000001350 alkyl halides Chemical class 0.000 description 1
• 229960000458 allantoin Drugs 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 239000008168 almond oil Substances 0.000 description 1
• CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 210000004727 amygdala Anatomy 0.000 description 1
• CVSVTCORWBXHQV-UHFFFAOYSA-N anhydrous creatine Natural products NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000001078 anti-cholinergic effect Effects 0.000 description 1
• 230000002082 anti-convulsion Effects 0.000 description 1
• 230000000561 anti-psychotic effect Effects 0.000 description 1
• 229940125681 anticonvulsant agent Drugs 0.000 description 1
• 229960003965 antiepileptics Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000000164 antipsychotic agent Substances 0.000 description 1
• 229940005529 antipsychotics Drugs 0.000 description 1
• 230000004596 appetite loss Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 239000003693 atypical antipsychotic agent Substances 0.000 description 1
• 229940127236 atypical antipsychotics Drugs 0.000 description 1
• 208000029560 autism spectrum disease Diseases 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 125000002785 azepinyl group Chemical group 0.000 description 1
• 229940116226 behenic acid Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 229940049706 benzodiazepine Drugs 0.000 description 1
• 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 208000028683 bipolar I disease Diseases 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 206010005159 blepharospasm Diseases 0.000 description 1
• 230000000744 blepharospasm Effects 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 150000001642 boronic acid derivatives Chemical class 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 230000003139 buffering effect Effects 0.000 description 1
• 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
• CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 229930003827 cannabinoid Natural products 0.000 description 1
• 239000003557 cannabinoid Substances 0.000 description 1
• 229940065144 cannabinoids Drugs 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
• 229960000623 carbamazepine Drugs 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
• 235000010418 carrageenan Nutrition 0.000 description 1
• 239000000679 carrageenan Substances 0.000 description 1
• 229920001525 carrageenan Polymers 0.000 description 1
• 229940113118 carrageenan Drugs 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 206010007776 catatonia Diseases 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 229920003086 cellulose ether Polymers 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 201000002866 cervical dystonia Diseases 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
• 238000001311 chemical methods and process Methods 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
• 208000021703 chronic tic disease Diseases 0.000 description 1
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
• 239000007979 citrate buffer Substances 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 229960003920 cocaine Drugs 0.000 description 1
• 230000003931 cognitive performance Effects 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 238000004891 communication Methods 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
• 229960003624 creatine Drugs 0.000 description 1
• 239000006046 creatine Substances 0.000 description 1
• 125000000392 cycloalkenyl group Chemical group 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
• 231100000868 delusion Toxicity 0.000 description 1
• 208000030964 dependent personality disease Diseases 0.000 description 1
• 230000000994 depressogenic effect Effects 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 150000008050 dialkyl sulfates Chemical class 0.000 description 1
• 229960002380 dibutyl phthalate Drugs 0.000 description 1
• 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
• 229940031578 diisopropyl adipate Drugs 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
• GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
• 235000014632 disordered eating Nutrition 0.000 description 1
• 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 229960003638 dopamine Drugs 0.000 description 1
• 239000000442 dopamine 2 receptor blocking agent Substances 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 229940125436 dual inhibitor Drugs 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 208000024732 dysthymic disease Diseases 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 150000002081 enamines Chemical class 0.000 description 1
• 201000002933 epilepsy with generalized tonic-clonic seizures Diseases 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
• 201000006517 essential tremor Diseases 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 229940116333 ethyl lactate Drugs 0.000 description 1
• 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 229940117360 ethyl pyruvate Drugs 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 210000000744 eyelid Anatomy 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 229960002464 fluoxetine Drugs 0.000 description 1
• 201000002865 focal hand dystonia Diseases 0.000 description 1
• 229940014144 folate Drugs 0.000 description 1
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
• 125000004613 furo[2,3-c]pyridinyl group Chemical group O1C(=CC=2C1=CN=CC2)* 0.000 description 1
• 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 230000000848 glutamatergic effect Effects 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 150000002315 glycerophosphates Chemical class 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• 239000000380 hallucinogen Substances 0.000 description 1
• 125000004970 halomethyl group Chemical group 0.000 description 1
• 239000011121 hardwood Substances 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• 125000001072 heteroaryl group Chemical group 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical class CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
• 150000002429 hydrazines Chemical class 0.000 description 1
• 150000007857 hydrazones Chemical class 0.000 description 1
• 150000002430 hydrocarbons Chemical group 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• 150000002431 hydrogen Chemical class 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• 230000001660 hyperkinetic effect Effects 0.000 description 1
• 206010020765 hypersomnia Diseases 0.000 description 1
• 239000003326 hypnotic agent Substances 0.000 description 1
• 230000000147 hypnotic effect Effects 0.000 description 1
• 230000001505 hypomanic effect Effects 0.000 description 1
• IJYHVZICHKCLMQ-UHFFFAOYSA-N imidazo[4,5-d]triazin-4-one Chemical class O=C1N=NN=C2N=CN=C12 IJYHVZICHKCLMQ-UHFFFAOYSA-N 0.000 description 1
• 125000002632 imidazolidinyl group Chemical group 0.000 description 1
• 125000002636 imidazolinyl group Chemical group 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 201000001881 impotence Diseases 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 208000018197 inherited torticollis Diseases 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 208000015046 intermittent explosive disease Diseases 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Natural products OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 1
• 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
• XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
• 229940089456 isopropyl stearate Drugs 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 239000000644 isotonic solution Substances 0.000 description 1
• 125000003971 isoxazolinyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 150000003951 lactams Chemical class 0.000 description 1
• 150000003903 lactic acid esters Chemical class 0.000 description 1
• PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
• 229960001848 lamotrigine Drugs 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 230000005976 liver dysfunction Effects 0.000 description 1
• 208000007903 liver failure Diseases 0.000 description 1
• 231100000835 liver failure Toxicity 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 230000007787 long-term memory Effects 0.000 description 1
• 208000019017 loss of appetite Diseases 0.000 description 1
• 235000021266 loss of appetite Nutrition 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• 208000024714 major depressive disease Diseases 0.000 description 1
• 150000002688 maleic acid derivatives Chemical class 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 1
• 206010027175 memory impairment Diseases 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
• 229920003087 methylethyl cellulose Polymers 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
• 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
• 229910052901 montmorillonite Inorganic materials 0.000 description 1
• 150000002780 morpholines Chemical class 0.000 description 1
• 230000007659 motor function Effects 0.000 description 1
• 230000036640 muscle relaxation Effects 0.000 description 1
• 230000002151 myoclonic effect Effects 0.000 description 1
• 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
• SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
• 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 208000037860 neuroleptic-induced Akathisia Diseases 0.000 description 1
• 150000002814 niacins Chemical class 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 150000002823 nitrates Chemical class 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical class CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 229960002748 norepinephrine Drugs 0.000 description 1
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
• BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 description 1
• XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
• 229940055577 oleyl alcohol Drugs 0.000 description 1
• BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 229940005483 opioid analgesics Drugs 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 239000012044 organic layer Substances 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 201000002851 oromandibular dystonia Diseases 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 150000003891 oxalate salts Chemical class 0.000 description 1
• 125000000160 oxazolidinyl group Chemical group 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 125000003566 oxetanyl group Chemical group 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 125000004095 oxindolyl group Chemical class N1(C(CC2=CC=CC=C12)=O)* 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 208000019906 panic disease Diseases 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000035778 pathophysiological process Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 230000000149 penetrating effect Effects 0.000 description 1
• 235000019371 penicillin G benzathine Nutrition 0.000 description 1
• 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
• 208000022821 personality disease Diseases 0.000 description 1
• JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
• 229950010883 phencyclidine Drugs 0.000 description 1
• FCJSHPDYVMKCHI-UHFFFAOYSA-N phenyl benzoate Chemical group C=1C=CC=CC=1C(=O)OC1=CC=CC=C1 FCJSHPDYVMKCHI-UHFFFAOYSA-N 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
• 235000011007 phosphoric acid Nutrition 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
• 125000005498 phthalate group Chemical class 0.000 description 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
• 125000005547 pivalate group Chemical group 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004584 polyacrylic acid Substances 0.000 description 1
• 239000008389 polyethoxylated castor oil Substances 0.000 description 1
• 229920000151 polyglycol Polymers 0.000 description 1
• 239000010695 polyglycol Substances 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 229940068965 polysorbates Drugs 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• 208000021011 postpartum psychosis Diseases 0.000 description 1
• 230000001242 postsynaptic effect Effects 0.000 description 1
• 229910000027 potassium carbonate Inorganic materials 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 210000002442 prefrontal cortex Anatomy 0.000 description 1
• 230000006977 prepulse inhibition Effects 0.000 description 1
• 238000002203 pretreatment Methods 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
• ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
• 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
• 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 102000004169 proteins and genes Human genes 0.000 description 1
• 230000005588 protonation Effects 0.000 description 1
• 230000001003 psychopharmacologic effect Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 210000002637 putamen Anatomy 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000002755 pyrazolinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• FFRYUAVNPBUEIC-UHFFFAOYSA-N quinoxalin-2-ol Chemical class C1=CC=CC2=NC(O)=CN=C21 FFRYUAVNPBUEIC-UHFFFAOYSA-N 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 238000010992 reflux Methods 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 208000023504 respiratory system disease Diseases 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 206010039083 rhinitis Diseases 0.000 description 1
• 238000011808 rodent model Methods 0.000 description 1
• 150000003873 salicylate salts Chemical class 0.000 description 1
• 229940125723 sedative agent Drugs 0.000 description 1
• 239000000932 sedative agent Substances 0.000 description 1
• 201000002899 segmental dystonia Diseases 0.000 description 1
• 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
• 230000036303 septic shock Effects 0.000 description 1
• 239000003352 sequestering agent Substances 0.000 description 1
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
• 208000022925 sleep disturbance Diseases 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 235000011069 sorbitan monooleate Nutrition 0.000 description 1
• 239000001593 sorbitan monooleate Substances 0.000 description 1
• 229940035049 sorbitan monooleate Drugs 0.000 description 1
• 235000011076 sorbitan monostearate Nutrition 0.000 description 1
• 239000001587 sorbitan monostearate Substances 0.000 description 1
• 229940035048 sorbitan monostearate Drugs 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 201000002849 spasmodic dystonia Diseases 0.000 description 1
• 201000001716 specific phobia Diseases 0.000 description 1
• 230000007480 spreading Effects 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 230000024188 startle response Effects 0.000 description 1
• 208000005809 status epilepticus Diseases 0.000 description 1
• 230000000707 stereoselective effect Effects 0.000 description 1
• 239000000021 stimulant Substances 0.000 description 1
• 150000003890 succinate salts Chemical class 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000005846 sugar alcohols Chemical class 0.000 description 1
• 239000007940 sugar coated tablet Substances 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 150000003892 tartrate salts Chemical class 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
• 125000006092 tetrahydro-1,1-dioxothienyl group Chemical group 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
• OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000006090 thiamorpholinyl sulfone group Chemical group 0.000 description 1
• 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
• 125000001984 thiazolidinyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 150000003567 thiocyanates Chemical class 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 229930003799 tocopherol Natural products 0.000 description 1
• 239000011732 tocopherol Substances 0.000 description 1
• 125000002640 tocopherol group Chemical class 0.000 description 1
• 235000019149 tocopherols Nutrition 0.000 description 1
• LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
• 230000001256 tonic effect Effects 0.000 description 1
• 208000018724 torsion dystonia Diseases 0.000 description 1
• 125000005490 tosylate group Chemical group 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 208000027100 transient tic disease Diseases 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 208000002271 trichotillomania Diseases 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 229940102566 valproate Drugs 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 235000019871 vegetable fat Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 210000001260 vocal cord Anatomy 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 235000010493 xanthan gum Nutrition 0.000 description 1
• 239000000230 xanthan gum Substances 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• 229940082509 xanthan gum Drugs 0.000 description 1
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1